[Selecting variants of drug treatment of non-complicated duodenal ulcer (based on a study of results of Rabeprazole efficiency)].

Abstract

This article presents considerations currently under discussion about the probability of HP participation in the ulcer causation as well as information about Rabeprazole efficiency for anti-helicobacter therapy of non-complicated duodenal ulcer (as a result of 7-day anti-helicobacter therapy, the healing of duodenal bulbs was recorded in 82.6% of cases; HP eradication was recorded in 86.9% of cases 4 weeks after the termination of the treatment) based on the analysis of scientific literature data and personal experience. Considerations related to the conduction of a possible study in the field of ulcer therapy that is not associated with Helicobacter pylori are presented.

• Authors: Iu B Vasil'ev
• Journal: Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology (Eksp Klin Gastroenterol) Issue 3 Pg. 14-8, 102 ( 2004) ISSN: 1682-8658 [Print] Russia (Federation)
• Vernacular Title: Vybor variantov medikamentoznoĭ terapiii neoslozhnennoĭ iazvennoĭ bolezni dvenadtsatiperstnoĭ kishki (po rezul'tatam izucheniia éffektivnosti rabeprazola).
• PMID: 15560394 (Publication Type: Journal Article, Review)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Ulcer Agents
• Benzimidazoles
• Rabeprazole
• Omeprazole

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Ulcer Agents (therapeutic use)
• Benzimidazoles (therapeutic use)
• Duodenal Ulcer (drug therapy, microbiology)
• Female
• Helicobacter Infections (complications, drug therapy)
• Helicobacter pylori (drug effects)
• Humans
• Male
• Omeprazole (analogs & derivatives, therapeutic use)
• Rabeprazole